2025-05-05 - Analysis Report
## Recursion Pharmaceuticals Inc. (RXRX) Stock Review

**0) Summary Statistics:**

RXRX, Recursion Pharmaceuticals Inc., is a biotechnology company focused on applying AI to drug discovery.  The company shows significant underperformance compared to the S&P 500 (VOO), with substantial negative returns and high risk indicators.  Recent earnings are negative, and while some positive revenue growth is observed, profitability remains elusive.


**1) Performance Comparison:**

* **RXRX Cumulative Return:** -46.88%
* **VOO (S&P 500) Cumulative Return:** 19.97%
* **Return Difference:** -66.9%
* **Relative Divergence:** 6.1% (This means the underperformance of RXRX relative to the S&P 500 falls at the 6.1st percentile of its historical range of underperformance.)

The provided alpha and beta analysis indicates high beta (2.3-4.0), suggesting RXRX's price movements are significantly more volatile than the market.  Negative alpha values consistently demonstrate underperformance relative to the market.  High maximum drawdown (MDD) consistently exceeding 70% underlines the significant risk associated with investing in RXRX.


**Alpha, Beta Analysis:**

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2021-2023  | 5.0% | 73.6% | -12.0% | 4.0 |
| 2022-2024  | 0.0% | 73.6% | -22.0% | 2.8 |
| 2023-2025  | 5.0% | 73.6% | -14.0% | 2.3 |


**2) Recent Price Movement:**

* **Closing Price:** $5.70
* **5-Day Moving Average:** $5.67
* **20-Day Moving Average:** $5.29
* **60-Day Moving Average:** $6.55

The price is currently trading below all three moving averages, suggesting a bearish trend.  The recent price increase of 3.64% (from $5.5 to $5.7) may indicate a temporary bounce, but further observation is needed to confirm a trend reversal.

**3) Technical Indicators:**

* **Market Risk Indicator (MRI):** 0.3776 (Medium Risk)
* **RSI:** 48.56 (Neutral; neither overbought nor oversold)
* **PPO:** 1.62 (Positive; suggesting bullish momentum, although the overall trend is bearish)
* **20-Day Relative Divergence Change:** -2.3% (Short-term bearish divergence)
* **Expected Return:** -565.3%  This extremely negative expected return highlights the significant risk and potential for further losses.  The negative expected return is likely related to the consistent negative EPS and the substantial underperformance against the S&P 500.  A long-term buy-and-hold strategy in this context would require careful consideration of significant potential losses relative to the S&P 500.

**4) Recent Earnings Analysis:**

| Date       | EPS     | Revenue      |
|------------|---------|--------------|
| 2024-11-06 | -$0.34  | $0.03B       |
| 2024-08-08 | -$0.40  | $0.01B       |
| 2024-05-09 | -$0.39  | $0.01B       |
| 2023-11-09 | -$0.43  | $0.01B       |
| 2024-11-06 | -$0.43  | $0.01B       |  *(Duplicate entry â€“ likely a data error)*


Consistent negative EPS indicates ongoing losses. While there's some recent improvement in revenue, profitability remains elusive.


**5) Financial Information:**

**Revenue and Profitability:**

| Quarter | Revenue | Profit Margin |
|---------|----------|---------------|
| 2024-12-31 | $0.00B | -183.62% |
| 2024-09-30 | $0.03B | 53.69% |
| 2024-06-30 | $0.01B | 36.14% |
| 2024-03-31 | $0.01B | 17.23% |
| 2023-12-31 | $0.01B | 6.99% |


**Capital and Profitability:**

| Quarter | Equity | ROE       |
|---------|---------|-----------|
| 2024-12-31 | $1.03B | -17.29%   |
| 2024-09-30 | $0.52B | -18.27%   |
| 2024-06-30 | $0.58B | -16.69%   |
| 2024-03-31 | $0.40B | -22.78%   |
| 2023-12-31 | $0.46B | -20.07%   |


The financial data shows significant volatility and consistent negative profitability,  with alarmingly negative profit margins and ROE, reflecting substantial financial challenges for the company.  The extremely high negative profit margin in Q4 2024 warrants closer investigation.


**6) Overall Analysis:**

Recursion Pharmaceuticals (RXRX) exhibits substantial risk and underperformance relative to the market.  Negative earnings, volatile financial performance, and a high beta suggest significant investment risk.  While a recent slight price increase offers a temporary glimmer of hope, the underlying fundamentals remain weak, indicating a high probability of further losses.  A long-term investment strategy should carefully consider the substantial underperformance relative to the S&P 500 and the potential for further significant losses.  More in-depth analysis, including competitive landscape and future pipeline projections, would be crucial before making any investment decisions.
